By Will Feuer
Purdue Pharma LP said the Food and Drug Administration has approved the company’s new drug application for Nalmefene hydrochloride injection, an opioid antagonist that has been shown to reverse opioid drug effects and manage overdoses.
The company said it will distribute injectable nalmefene for no profit.
“Nalmefene is an important part of our commitment to help abate the opioid crisis,” Purdue Chief Executive Dr. Craig Landau said. “Nalmefene will be an important treatment option to address the opioid crisis, which has accelerated during the Covid-19 pandemic and is being fueled by the increasing prevalence of illicitly manufactured synthetic opioids.”
In 2020, Purdue pleaded guilty to three federal felonies related to the marketing and distribution of OxyContin, a painkiller that has played a role in the opioid crisis in the US
Write to Will Feuer at Will.Feuer@wsj.com